NCT06084936 (GLOBRYTE) is a Phase 3 clinical trial of Obinutuzumab in Lymphoma, sponsored by Hoffmann-La Roche.

Who is sponsoring NCT06084936?

NCT06084936 is sponsored by Hoffmann-La Roche.

What drugs are being tested in NCT06084936?

Interventions in NCT06084936: Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide, Tocilizumab.

Is NCT06084936 still recruiting?

NCT06084936 is currently recruiting now. Last updated 2 April 2026.

Last reviewed 2026-04-02 · How we verify

NCT06084936: GLOBRYTE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Recruiting now Phase 3 Last updated 2 April 2026

What this trial tests

Phase 3 trial testing Obinutuzumab in Lymphoma in 182 participants. Currently enrolling.

Timeline

22 October 2023

Primary endpoint
31 August 2027

31 March 2028

Quick facts

Lead sponsor	Hoffmann-La Roche
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	182
Start date	22 October 2023
Primary completion	31 August 2027
Estimated completion	31 March 2028
Sites	75 locations across France, Italy, Sweden, Taiwan, United Kingdom, South Korea, Canada, Puerto Rico

Drugs / interventions tested

Obinutuzumab — full drug profile →
Glofitamab
Rituximab
Bendamustine (BENDAMUSTINE) — full drug profile →
Lenalidomide — full drug profile →
Tocilizumab (tocilizumab) — full drug profile →

Conditions studied

Lymphoma — all drugs for Lymphoma →

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

18 and older, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study.
Phillips TJ, Carlo-Stella C, Morschhauser F, Bachy E, et al · · 2025 · cited 45× · PMID 39365960 · DOI 10.1200/jco.23.02470
The Development and Application of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma.
Sun L, Romancik JT. · · 2025 · cited 5× · PMID 39997328 · DOI 10.3390/jpm15020051
Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.
Nylund P, Nikkarinen A, Ek S, Glimelius I. · · 2024 · cited 5× · PMID 38566987 · DOI 10.3389/fimmu.2024.1373269
Toxicities associated with lymphoma-targeting bispecific antibodies-a review.
Doig C, Yannakou CK. · · 2025 · cited 2× · PMID 40672834 · DOI 10.3389/fmed.2025.1582975
T-cell-based therapies for treating relapsed or refractory mantle cell lymphoma.
Epstein-Peterson ZD, Palomba ML. · · 2024 · cited 2× · PMID 39644075 · DOI 10.1182/hematology.2024000657
T-Cell-Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions.
Caserta S, Martino EA, Vigna E, Bruzzese A, et al · · 2026 · cited 1× · PMID 41207679 · DOI 10.1111/ejh.70063
Updates on the Biological Heterogeneity of Mantle Cell Lymphoma.
Ip A, Kabat M, Fogel L, Alkhatatneh H, et al · · 2025 · cited 1× · PMID 40002289 · DOI 10.3390/cancers17040696
Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions.
Tavarozzi R, Maher N, Catania G, Zacchi G, et al · · 2026 · PMID 41986622 · DOI 10.1038/s41375-026-02942-1

Verify or expand the search:

Other trials of Obinutuzumab

Trials testing the same drug.

NCT07003295 — Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease R · Phase 2 · recruiting
NCT07502872 — TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-g · Phase 2 · not yet recruiting
NCT07218510 — Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Smal · Phase 2 · recruiting
NCT07480850 — Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma · Phase 2 · active not recruiting
NCT07261163 — Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma · Phase 2 · not yet recruiting

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other Hoffmann-La Roche trials

Trials by the same sponsor.

NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06084936 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 2 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06084936.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing